William W. Greenfield
Professor
Also affiliated: Arkansas Children's Hospital (2014); Arkansas Department of Agriculture (2015); Arkansas Department of Health (2024); Beijing Obstetrics and Gynecology Hospital (2007)
Faculty Researcher
Obstetrics & Gynecology, College of Medicine
Research Areas
Biomedical Subjects
Biography and Research Information
OverviewAI-generated summary
Dr. William W. Greenfield's research focuses on human papillomavirus (HPV) infections, particularly in relation to cervical intraepithelial neoplasia (CIN) and cervical cancer. His work has investigated the evaluation of DNA extraction protocols from cytology specimens for studying cervical microbiota and has explored therapeutic vaccine approaches, such as the peptide-based HPV therapeutic vaccine PepCan, in clinical trials for treating CIN2/3. He has also examined the immune responses generated by these therapeutic interventions. Dr. Greenfield's research interests extend to maternal health, including the assessment of public maternal health dashboards in the United States and personal birth experiences among labor and delivery staff. His background includes a pharmacy degree from Auburn University and extensive training in obstetrics and gynecology, including da Vinci Robotic Surgery. He holds an h-index of 11 with 27 publications and 407 citations, and he collaborates with researchers at the University of Arkansas for Medical Sciences.
Research Overview
Dr. William Greenfield completed his medical degree at Meharry Medical College in Nashville, Tennessee, completed an internship at Baylor College of Medicine in Houston, Texas, and his residency in Obstetrics and Gynecology at the University of Arkansas for Medical Sciences in Little Rock. Before attending medical school, he received a pharmacy degree from Auburn University. His clinical interests are in obstetrics and gynecology. He is trained in daVinci Robotic Surgery. He has made presentations nationally, regionally and locally on topics in his field. Dr. Greenfield currently serves as the Arkansas Section Chair for the American Congress of Obstetrics and Gynecology, and is a member of several professional organizations including:Arkansas Medical SocietyAmerican Medical AssociationAmerican Society of Colposcopy and Cervical PathologyDr. Greenfield enjoys both his obstetric and gynecologic patients. He likes to help educate his patients and guide them to make informed decisions about their healthcare.
Metrics
- h-index: 11
- Publications: 27
- Citations: 413
Selected Publications
-
Maternity Care Team Members’ Perspectives on Barriers and Facilitators to Integrating Doulas into the Hospital Setting (2026)
-
Personal Birth Experiences and Clinician Attitudes About Cesarean Birth: A Cross‐Sectional Study With Female Labor and Delivery Unit Staff (2026)
-
A Randomized Double-Blind Phase 2 Clinical Trial Treating Cervical Intraepithelial Neoplasia 2/3 with PepCan or <i>Candida</i> (2025)
-
Immune responses in a phase 2 clinical trial of peptide-based therapeutic human papillomavirus vaccine, PepCan, versus <i>Candida</i> adjuvant alone in treating cervical intraepithelial neoplasia 2/3. (2024)
-
Public Maternal Health Dashboards in the United States: Descriptive Assessment (2024)
-
Maternal Mortality Review Committee findings: awareness and recommended dissemination strategies in Arkansas (2024)
-
A peptide-based human papillomavirus therapeutic vaccine, PepCan, or <i>Candida</i> adjuvant alone in treatment of cervical intraepithelial neoplasia 2/3 (CIN2/3). (2023)
-
Quarantine and isolation facility: A State Health Department’s response to the COVID-19 pandemic (2021)
-
Evaluation of DNA extraction protocols from liquid-based cytology specimens for studying cervical microbiota (2021)
-
Evaluation of DNA extraction protocols from liquid-based cytology specimens for studying cervical microbiota (2020)
-
Cervical Microbiome and Response to a Human Papillomavirus Therapeutic Vaccine for Treating High-Grade Cervical Squamous Intraepithelial Lesion (2019)
-
Cervical microbiome role in outcomes of therapeutic HPV vaccination for cervical intraepithelial neoplasia. (2018)
-
Human papillomavirus type 16 viral load is decreased following a therapeutic vaccination (2016)
-
A phase I dose-escalation clinical trial of a peptide-based human papillomavirus therapeutic vaccine with <i>candida </i>skin test reagent as a novel vaccine adjuvant for treating women with biopsy-proven cervical intraepithelial neoplasia 2/3. (2015)
-
A novel use of a statewide telecolposcopy network for recruitment of participants in a Phase I clinical trial of a human papillomavirus therapeutic vaccine (2015)
Grants & Funding
As listed on this researcher's institutional profile.
- DP24-004, PRC, Core: Health Promotion and Disease Prevention Research Centers NIH Co-Investigator
- Understanding and Enhancing T-Cell Responses to High Risk Human Papillomaviruses-Renewal NIH Co-Investigator
- The Arkansas Perinatal Quality Collaborative Centers for Disease Control & Prevention Co-Principal Investigator
Collaboration Network
Top Collaborators
- Evaluation of DNA extraction protocols from liquid-based cytology specimens for studying cervical microbiota
- A peptide-based human papillomavirus therapeutic vaccine, PepCan, or <i>Candida</i> adjuvant alone in treatment of cervical intraepithelial neoplasia 2/3 (CIN2/3).
- A Randomized Double-Blind Phase 2 Clinical Trial Treating Cervical Intraepithelial Neoplasia 2/3 with PepCan or <i>Candida</i>
- Immune responses in a phase 2 clinical trial of peptide-based therapeutic human papillomavirus vaccine, PepCan, versus <i>Candida</i> adjuvant alone in treating cervical intraepithelial neoplasia 2/3.
- Evaluation of DNA extraction protocols from liquid-based cytology specimens for studying cervical microbiota
- A peptide-based human papillomavirus therapeutic vaccine, PepCan, or <i>Candida</i> adjuvant alone in treatment of cervical intraepithelial neoplasia 2/3 (CIN2/3).
- A Randomized Double-Blind Phase 2 Clinical Trial Treating Cervical Intraepithelial Neoplasia 2/3 with PepCan or <i>Candida</i>
- Immune responses in a phase 2 clinical trial of peptide-based therapeutic human papillomavirus vaccine, PepCan, versus <i>Candida</i> adjuvant alone in treating cervical intraepithelial neoplasia 2/3.
- Evaluation of DNA extraction protocols from liquid-based cytology specimens for studying cervical microbiota
- A peptide-based human papillomavirus therapeutic vaccine, PepCan, or <i>Candida</i> adjuvant alone in treatment of cervical intraepithelial neoplasia 2/3 (CIN2/3).
- A Randomized Double-Blind Phase 2 Clinical Trial Treating Cervical Intraepithelial Neoplasia 2/3 with PepCan or <i>Candida</i>
- Immune responses in a phase 2 clinical trial of peptide-based therapeutic human papillomavirus vaccine, PepCan, versus <i>Candida</i> adjuvant alone in treating cervical intraepithelial neoplasia 2/3.
- Evaluation of DNA extraction protocols from liquid-based cytology specimens for studying cervical microbiota
- A peptide-based human papillomavirus therapeutic vaccine, PepCan, or <i>Candida</i> adjuvant alone in treatment of cervical intraepithelial neoplasia 2/3 (CIN2/3).
- A Randomized Double-Blind Phase 2 Clinical Trial Treating Cervical Intraepithelial Neoplasia 2/3 with PepCan or <i>Candida</i>
- A peptide-based human papillomavirus therapeutic vaccine, PepCan, or <i>Candida</i> adjuvant alone in treatment of cervical intraepithelial neoplasia 2/3 (CIN2/3).
- A Randomized Double-Blind Phase 2 Clinical Trial Treating Cervical Intraepithelial Neoplasia 2/3 with PepCan or <i>Candida</i>
- Immune responses in a phase 2 clinical trial of peptide-based therapeutic human papillomavirus vaccine, PepCan, versus <i>Candida</i> adjuvant alone in treating cervical intraepithelial neoplasia 2/3.
- A peptide-based human papillomavirus therapeutic vaccine, PepCan, or <i>Candida</i> adjuvant alone in treatment of cervical intraepithelial neoplasia 2/3 (CIN2/3).
- A Randomized Double-Blind Phase 2 Clinical Trial Treating Cervical Intraepithelial Neoplasia 2/3 with PepCan or <i>Candida</i>
- Immune responses in a phase 2 clinical trial of peptide-based therapeutic human papillomavirus vaccine, PepCan, versus <i>Candida</i> adjuvant alone in treating cervical intraepithelial neoplasia 2/3.
- A peptide-based human papillomavirus therapeutic vaccine, PepCan, or <i>Candida</i> adjuvant alone in treatment of cervical intraepithelial neoplasia 2/3 (CIN2/3).
- A Randomized Double-Blind Phase 2 Clinical Trial Treating Cervical Intraepithelial Neoplasia 2/3 with PepCan or <i>Candida</i>
- Immune responses in a phase 2 clinical trial of peptide-based therapeutic human papillomavirus vaccine, PepCan, versus <i>Candida</i> adjuvant alone in treating cervical intraepithelial neoplasia 2/3.
- A peptide-based human papillomavirus therapeutic vaccine, PepCan, or <i>Candida</i> adjuvant alone in treatment of cervical intraepithelial neoplasia 2/3 (CIN2/3).
- A Randomized Double-Blind Phase 2 Clinical Trial Treating Cervical Intraepithelial Neoplasia 2/3 with PepCan or <i>Candida</i>
- Immune responses in a phase 2 clinical trial of peptide-based therapeutic human papillomavirus vaccine, PepCan, versus <i>Candida</i> adjuvant alone in treating cervical intraepithelial neoplasia 2/3.
- A peptide-based human papillomavirus therapeutic vaccine, PepCan, or <i>Candida</i> adjuvant alone in treatment of cervical intraepithelial neoplasia 2/3 (CIN2/3).
- A Randomized Double-Blind Phase 2 Clinical Trial Treating Cervical Intraepithelial Neoplasia 2/3 with PepCan or <i>Candida</i>
- Immune responses in a phase 2 clinical trial of peptide-based therapeutic human papillomavirus vaccine, PepCan, versus <i>Candida</i> adjuvant alone in treating cervical intraepithelial neoplasia 2/3.
- A peptide-based human papillomavirus therapeutic vaccine, PepCan, or <i>Candida</i> adjuvant alone in treatment of cervical intraepithelial neoplasia 2/3 (CIN2/3).
- A Randomized Double-Blind Phase 2 Clinical Trial Treating Cervical Intraepithelial Neoplasia 2/3 with PepCan or <i>Candida</i>
- Immune responses in a phase 2 clinical trial of peptide-based therapeutic human papillomavirus vaccine, PepCan, versus <i>Candida</i> adjuvant alone in treating cervical intraepithelial neoplasia 2/3.
- Public Maternal Health Dashboards in the United States: Descriptive Assessment
- Maternal Mortality Review Committee findings: awareness and recommended dissemination strategies in Arkansas
- Personal Birth Experiences and Clinician Attitudes About Cesarean Birth: A Cross‐Sectional Study With Female Labor and Delivery Unit Staff
- Maternal Mortality Review Committee findings: awareness and recommended dissemination strategies in Arkansas
- Personal Birth Experiences and Clinician Attitudes About Cesarean Birth: A Cross‐Sectional Study With Female Labor and Delivery Unit Staff
- Maternity Care Team Members’ Perspectives on Barriers and Facilitators to Integrating Doulas into the Hospital Setting
- A peptide-based human papillomavirus therapeutic vaccine, PepCan, or <i>Candida</i> adjuvant alone in treatment of cervical intraepithelial neoplasia 2/3 (CIN2/3).
- A Randomized Double-Blind Phase 2 Clinical Trial Treating Cervical Intraepithelial Neoplasia 2/3 with PepCan or <i>Candida</i>
- A peptide-based human papillomavirus therapeutic vaccine, PepCan, or <i>Candida</i> adjuvant alone in treatment of cervical intraepithelial neoplasia 2/3 (CIN2/3).
- A Randomized Double-Blind Phase 2 Clinical Trial Treating Cervical Intraepithelial Neoplasia 2/3 with PepCan or <i>Candida</i>
- A peptide-based human papillomavirus therapeutic vaccine, PepCan, or <i>Candida</i> adjuvant alone in treatment of cervical intraepithelial neoplasia 2/3 (CIN2/3).
- A Randomized Double-Blind Phase 2 Clinical Trial Treating Cervical Intraepithelial Neoplasia 2/3 with PepCan or <i>Candida</i>
Similar Researchers
Based on overlapping research topics